CSR at Galapagos – Summary

CSR at Galapagos – Summary

Material Aspect 1: Improving people’s lives

SDG
SDG 3 (icon) SDG 9 (icon) SDG 17 (icon)
Areas of engagement
  • We are pioneering for patients and our mission is to discover and develop innovative medicines that address high unmet medical needs
  • Our science and innovation is based on our flexible target discovery platform
  • We commit to an ambitious R&D goal of maintaining an active portfolio of 30 projects
  • We are building a deep early-stage R&D pipeline
  • Pending potential approval, we expect to launch our first drug, filgotinib in RA, in 2020, with additional indications to follow in the coming years
  • We aim to bring our innovation to patients suffering from severe diseases, includig in IPF
  • We accelerate innovation through win-win partnerships

Go to chapter

Material Aspect 2: Our employees are the strength behind Galapagos

SDG
SDG 3 (icon) SDG 4 (icon) SDG 5 (icon) SDG 8 (icon) SDG 10 (icon)
Areas of engagement
  • We strive for gender equality
  • We aim to continue to develop an inclusive and diverse workforce
  • We have implemented a program that is designed to reward, recognize and retain employees
  • Our involvement in local communities and charities

Go to chapter

Material Aspect 3: Conducting business ethically and responsibly

SDG
SDG 3 (icon) SDG 4 (icon) SDG 17 (icon)
Areas of engagement
  • Animal welfare in drug development
  • Our clinical trials ethics
  • Access to our medicines
  • Our code of business conduct and ethics

Go to chapter

Material Aspect 4: We care about the environment, health and safety

SDG
SDG 3 (icon) SDG 8 (icon) SDG 13 (icon)
Areas of engagement
  • We strive for a minimal environmental impact
  • We are compliant with our sector rules and regulations
  • We go digital as much as possible
  • We established a company-wide EHS framework

Go to chapter